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Primary plasma cell leukemia (pPCL) is an uncommon but aggressive plasma cell malignancy associated with
frequent extramedullary involvement, high-risk cytogenetic abnormalities, and frequent organ dysfunction,
ultimately resulting in poor prognosis. Here we review recent advances in our understanding of the molecular
and biological aspects of PCL and summarize therapeutic progress occurring over the past 2 decades. pPCL is
distinguished from secondary PCL arising from multiple myeloma. The molecular and immunophenotypic
changes of pPCL are often distinct from those seen in secondary PCL and multiple myeloma. The availability of
novel agents (ie, proteasome inhibitors and immunomodulatory agents) and the increasing use of hemato-
poietic cell transplantation strategies have resulted in better outcomes, although long-term survival remains
poor. Development of complex treatment algorithms that combine novel agents as induction therapy, as part
of conditioning regimens for hematopoietic cell transplantation (autologous or allogeneic), or as post-
transplantation remission strategies are logical and may translate into improved survival in patients with PCL.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION bortezomib appear to be active against PCL, but data are still
Plasma cell leukemia (PCL) accounts for 0.3% of cases of
acute leukemia, up to 4% of multiple myeloma (MM)-asso-
ciated presentations, and 12% of cases of MM with high
tumor burden [1,2], and most commonly presents with
circulating plasma cells and an aggressive clinical course. The
deﬁnition of PCL, as established by Kyle et al. [3], requires the
presence of an absolute plasma cell count>2000/mL or>20%
plasma cells in peripheral WBCs [4]. The disease may be
primary (pPCL), presenting de novo, or may evolve during
the course of relapsed or progressive MM, termed secondary
(sPCL) [5,6]. The overall prognosis of PCL is generally poor
compared with that of MM. Notwithstanding that both pPCL
and sPCL might share similar biological and clinical courses,
sPCL generally represents a more aggressive and fulminant
plasma cell disorder, with a median survival of a fewmonths
(1.3 months for sPCL versus 11.1 months for pPCL) [7].
The overall prognosis of pPCL is also poor, with reported
survival expectancy of less than 1 year in themajority of cases
[1,2], considerably shorter than that of patients with MM
with a high tumor burden [1]. Moreover, pPCL is associated
with early mortality [8]. The optimal front-line therapy for
patients with pPCL remains undeﬁned; novel agents such asedgments on page 1150.
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13.02.003largely limited to institutional case series and case reports
[1,2,9]. Hematopoietic cell transplantation (HCT), both
autologous and allogeneic, has proven feasible based on
small series and retrospective registry analysis; however,
prospective randomized controlled data are lacking.
Here we provide a comprehensive review that evaluates
the current understanding of the biological and genetic
aspects of PCL, as well as recent therapeutic advances
including conventional chemotherapy, novel agents, and
autologous and allogeneic HCT. A suggested treatment
strategy is discussed, and future therapeutic options are
explored.
LITERATURE SEARCH STRATEGY
A comprehensive medical literature search was con-
ducted using PubMed (1966 to November 23, 2012), with the
following search strategy: “Leukemia, Plasma Cell” (MeSH). A
total of 774 publications were identiﬁed, with 394 deemed
relevant to PCL and 380 not relevant to PCL. Relevant articles
focusing on chemotherapy, autologous HCT, and allogeneic
HCT were selected. For the purpose of this review, single case
reports were excluded. Findings from these selected articles
are summarized herein.
CHARACTERISTICS OF PCL
Clinical
The median age at diagnosis of PCL is 53-57 years, at least
a decade younger than the median age at diagnosis of MM
[1,7,9,10]. A recent report based on the Surveillance, Epide-
miology, and End Results database identiﬁed at total of 291Transplantation.
T. Nishihori et al. / Biol Blood Marrow Transplant 19 (2013) 1144e1151 1145patients with PCL between 1973 and 2004, with a median
age of 67 years (range, 19 to 98 years) [11]. However, that
analysis did not distinguish pPCL from sPCL, and literature on
chemotherapy and HCT may have an inherent selection bias
for reporting results of younger patients with good perfor-
mance status. The reported percentage of pPCL cases in
males varies from 38% to 60% [2,7,9,12].
Clinically, patients with PCL may present with extra-
medullary involvement (14%-23%), hepatomegaly (7%-73%),
splenomegaly (18%-53%), lymphadenopathy (3%-40%),
elevated lactate dehydrogenase, hypercalcemia, hypo-
albuminemia, and thrombocytopenia (median platelet count,
62-123  109/L) [1-3,7,9,13]. Renal impairment is common
(serum creatinine>2mg/dL), and is seen in 33%-53% of cases
[2,7,13]. Leptomeningeal inﬁltration has been reported.
Interestingly, skeletal lytic lesions are less common in
pPCL (35%-67%) compared with sPCL or MM (79%-81%)
[2,7,9,10,13].
Genetic and Molecular
Cytogenetic changes, including hypodiploidy, pseudodi-
ploidy, complex karyotype, and monosomy 13, are more
common in PCL than in MM [2,8,14]. Deletion of 13q by
ﬂuorescence in situ hybridization can be detected in up to
85% of cases of pPCL [2,7]. Deletions or mutation of p53
conferring adverse prognosis has been reported more
frequently in PCL compared with MM (20%-56% in pPCL and
83% in sPCL versus 10%-15% in MM) [7,15-18]. Chromosome 1
abnormalities are often seen in association with PCL [19].
Ampliﬁcation of 1q21 and deletion 1p21 are more common
in PCL (46%-67% and 21%-44%, respectively) than in MM
(30%-43% and 20%-36%, respectively), contributing to the
worse prognosis in PCL [16-18,20-22]. Chang et al. [20] re-
ported a signiﬁcantly greater increase in ampliﬁcation of the
cyclin-dependent kinase regulatory subunit 1 (CKS1B) gene
in patients with PCL (62%) compared with patients with MM
(relapsed, 52%; newly diagnosed, 36%; 0% in cases of mono-
clonal gammopathy of undetermined signiﬁcance) (P< .001).
Interestingly, immunoglobulin heavy chain (IgH) trans-
locations in patients with primary PCL selectively involve
11q13 (cyclin D1 [CCND1]), likely supporting a key patho-
genic role in such cases [7]. On the other hand, multiple
partner oncogenes appear to be involved in the development
of sPCL, including 11q13, 4p16 (ﬁbroblast growth factor
receptor 3 [FGFR3]/multiple myeloma SET domain [MMSET]),
and 16q23 (macrophage activating factor [MAF]), among
others [7].
The progressive decline in CD38 expression from normal
plasma cells to monoclonal gammopathy to MM and then to
PCL likely indicates a dedifferentiated state in PCL [22].
Overexpression of CD27 may play a role in the biology of PCL
through activation of the nuclear factor-kB pathway and
exertion of antiapoptotic properties [23,24].
Hallmarks of PCL are extramedullary invasion, the ability
to recirculate in blood, and expansion of plasma cells inde-
pendent of the putative protective bone marrow microen-
vironment niche. One hypothesis associates lower
expression of CD56 (which is typically expressed in malig-
nant plasma cells), neuronal cell adhesion molecule, and
leukocyte function-associated antigen 1 on clonal plasma
cells with the tendency to form nodular plasma cell aggre-
gates, and hence the leukemic presentation [2,25]. Elevated
levels of death receptor CD95 have been reported in patients
with PCL [22]. Up-regulation and rearrangements of the Myc
proto-oncogene are associated with worse prognosis in pPCL[7,17,26]. Activating mutations of NRAS and KRAS are seen
more frequently in pPCL compared to MM [7,27]. In addition,
gene expression proﬁling of pPCL appears to show a distinct
clustering, and pPCL may be a subentity of MM based on
gene expression proﬁling ﬁndings [28].
THERAPEUTIC MODALITIES
Conventional and Combination Chemotherapy
Before embarking on the treatment of PCL, it is impor-
tant to rule out benign reactive plasmacytosis, which is
commonly associated with infections and rheumatologic
conditions [29]. Reactive plasmacytosis maymimic PCL but is
polyclonal in nature; careful immunophenotyping with ﬂow
cytometry is essential to differentiate the 2 conditions [30].
Data are limited on therapeutic options for patients with
PCL, owing in part to early mortality and lack of prospective
trials speciﬁc for patients with PCL. Conventional regimens
using standard-dose alkylator-based therapy without novel
agents have provided disappointing results [1]. A series of 12
patients with pPCL treated with melphalan plus prednisone
had a median survival of only 2-3 months [2].
Multiagent systemic conventional chemotherapy regi-
mens may offer prolonged survival. One study reported
a median survival of 18 months in patients treated with
combination chemotherapy (ie, vincristine, cyclophospha-
mide, melphalan and prednisone/vincristine; bleomycin,
adriamycin, and prednisone), compared with only 3 months
in those treated with melphalan plus prednisone [2].
Another report indicated that intermediate dose melphalan
(80 mg/m2 orally per cycle with dexamethasone) was asso-
ciated with better survival than a vincristine, doxorubicin,
and dexamethasone regimen in patients with pPCL [12].
The availability of novel agents, including proteasome
inhibitors and immunomodulatory agents, has improved
outcomes in patients with PCL [31]. A retrospective study of
128 patients with PCL by Gruppo Italiano Malattie Emato-
logiche dell’Adulto (GIMEMA) between 2000 and 2008
suggested improved survival after bortezomib or thalido-
mide therapy [31]. Several case reports and small case series
have demonstrated a beneﬁt of bortezomib, alone and in
combination with other agents, in patients with PCL [32-34].
Selected studies on novel agents in treatment of PCL are
summarized in Table 1.
Thalidomide as a single agent does not appear to be
sufﬁciently efﬁcacious for treating PCL [35]. The use of
thalidomide as a maintenance option after autologous HCT
had been explored [36-38]; however, this option may be
obsolete today, considering lenalidomide’s better efﬁcacy
and tolerability. Combination chemotherapy incorporating
thalidomide may demonstrate enhanced activity [39,40], but
the data are not based on randomized controlled studies.
GIMEMA also reported a retrospective analysis of 29
patients with pPCL who received front-line bortezomib-
containing regimens between 2006 and 2010 [41]. The
overall response rate was 79%, with 38% very good partial
response (VGPR) or better, and renal function improved in 10
of the 11 patients with renal impairment. A 2-year
progression-free survival (PFS) of 40% and 2-year overall
survival (OS) of 55% were reported. The data suggested that
a bortezomib-based induction regimen might be associated
with better long-term outcomes after autologous HCT
consolidation [41]. Other studies have also reported
improved survival with bortezomib-containing regimens
[31,42,43]; however, the experience from the Arkansas group
and the Intergroupe Francophone de Myéloma did not
Table 1
Selected Studies of Chemotherapy in PCL (Reporting 3 Cases)
Author Number
of Subjects
(Median
Age, Years)
Study Type Chemotherapy Regimen, n Response Proceeded to HCT Toxicities Survival
Pagano et al. [31] 73 (N/A) Retrospective
(pPCL; GIMEMA)
VAD, 36; VT, 10; Cy, 9; Mel, 8;
Thal, 5; bortezomib, 4
CR, 31%; PR, 25% 23/72 (32%) N/A 51 deaths; median OS,
12.6 months
Avet-Loiseau et al. [15] 70 (60) Retrospective
(pPCL; IFM)
Various (those age <65
received either VAD or VD)
N/A N/A N/A No survival beneﬁt with
bortezomib
D’Arena et al. [41] 29 (62) Retrospective
(pPCL)
Various bortezomib-containing
regimens
CR, 28%; VGPR, 10%;
PR, 41%
12/29 (auto-HCT, 7;
allo-HCT, 5) (41%)
Grade 3/4 hematologic (20%),
neurology (21%), infection (16%)
16 patients alive after a
median of 24 months
follow-up
Lebovic et al. [43] 25 (59) Retrospective
(pPCL, 13; sPCL, 12)
Bortezomib-based, 18;
lenalidomide-based, 7
CR, 36%; VGPR, 8%; PR,
44%; SD, 4%
16/25 (64%) N/A Median OS, 23.6 months
(28 months for bortezomib-based
versus 4 months for
nonebortezomib-based)
Vela-Ojeda et al. [12] 24 (64) Retrospective VAD, 12; M-80, 8; VMCPA, 4 VAD: CR, 0; PR, 0; M-80:
CR, 2; PR, 4; VMCPA: CR, 1;
PR, 0
2/8 M-80 Grade 3/4 hematologic, grade 3/4
diarrhea
Median OS, 60 days
Musto et al. [18] 23 (62) Phase 2 (pPCL) Rev/Dex* CR, 13%; nCR, 4%; VGPR, 17%;
PR, 26%
6/23 (26%) Acute renal failure, Steven-Johnson
syndrome, pneumonia
At 15-month follow-up, PFS,
52.1%; OS, 65.2%
Lebon et al. [72] 20 (56) Retrospective
(pPCL, 3; sPCL, 17)
PAD, 20 CR, 10%; VGPR, 50%; PR, 20%;
SD, 10%
19/20 (auto-HCT, 18;
allo-HCT, 1)
1 died of pulmonary hypertension,
3 DVT
5 relapsed, 1-year OS, 95%
Musto et al. [42] 12 (61) Retrospective
(pPCL, 8; sPCL, 4)
PAD, 5; VTD/VT, 3;
bortezomib, 4
CR, 2; VGPR, 4; PR, 5; SD, 1 3/12 (25%) auto-HCT Grade 3/4 hematologic, infections Median PFS, 8 months; median OS,
12 months
Finnegan et al. [66] 5 (57) Case series (pPCL) PAD, 2; bortezomib single
agent, 2; VD, 1
CR, 2 (PAD regimen) 2 auto-HCT Disseminated zoster, 1 1 alive in CR at 9 months after
auto-HCT; 1 relapse at 8 months
post-HCT; 3 deaths
Petrucci et al. [35] 5 (68) Case series
(pPCL, 2; sPCL, 3)
Thalidomide No response None N/A All dead within 120 days
Johnston et al. [36] 4 (60) Case series
(pPCL, 2; sPCL, 2)
Thalidomide PR, 2; SD, 1; REL/PROG, 1 N/A N/A 2 deaths; 2 alive at 7 and 15 months
Al-Nawakil et al. [78] 4 (65) Case series
(pPCL, 2; sPCL, 2)
PAD, 4 CR, 1; VGPR, 3 2 second salvage
auto-HCTs
Grade 2 neuropathy, grade 4
pancytopenia
2 alive in CR at 8 and 22 months after
autologous HCT; 2 in VGPR at 9 and
12 months
Murthy et al. [40] 3 (53) Case series (pCL) Hyper-CVAD  thalidomide CR, 3 2/3 N/A 1 relapse; all alive
Katodritou et al. [24] 3 (63) Case series (pPCL) VD; bortezomib maintenance CR, 2; VGPR, 1 N/A Hypotension, neuropathy Alive at 14, 21, and 27 months
Allo indicates allogeneic; auto, autologous; Cy, cyclophosphamide; Dex, dexamethasone; DVT, deep vein thrombosis; IFM, Intergroupe Francophone de Myéloma; M-80, oral melphalan 80 mg/m2, dexamethasone; hyper-CVAD,
fractionated high-dose cyclophosphamide, dexamethasone, infusional vincristine, and doxorubicin; Mel, melphalan; MR, minimal response; N/A, not available; nCR, near complete response; NR, no response; PAD, bortezomib
(PS-341), doxorubicin, dexamethasone; Rev, lenalidomide (Revlimid); REL/PROG, relapse or progression; SD, stable disease; sPCL, secondary plasma cell leukemia; VAD, vincristine, doxorubicine, and dexamethasone; VD,
bortezomib and dexamethasone; VMCPA, vincristine, melphalan, cyclophosphamide, prednisone, and doxorubicin; VMP, bortezomib (Velcade), melphalan, and prednisone; VT, bortezomib (Velcade) and thalidomide; VTD,
bortezomib (Velcade), thalidomide, and dexamethasone.
* Fourteen patients (61%) completed at least 4 cycles.
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Bortezomib may be associated with a risk of tumor lysis
syndrome in patients with PCL, owing to high tumor
burden [44].
Combinations of lenalidomide and other agents have
been examined as well [45,46]. Musto et al. [18] reported
a Phase II study evaluating the combination of lenalidomide
and dexamethasone in pPCL. Partial response (PR) was ach-
ieved in 61%, and VGPR or better was achieved in 35%.
Combination regimens incorporating lenalidomide have
been investigated in relapsed/refractory settings [46,47];
however, lenalidomide use may be limited by the fact that
many patients with PCL present with renal insufﬁciency,
which hinders therapy with this agent.
Multiagent combination regimens incorporating novel
agents appear to show promising results including lenali-
domide, bortezomib, and dexamethasone [48,49]; bor-
etezomib, thalidomide, and dexamethasone [41,42];
melphalan, lenalidomide, and dexamethasone [47]; and
melphalan, prednisone, bortezomib, and thalidomide [41].
Future prospective studies are needed to establish the most
efﬁcacious regimens in PCL treatment.
Chemotherapy resistance has been associated with
extremely poor prognosis in PCL, with survival estimates of
only a fewmonths [12,50]. The slow clearance of plasma cells
from peripheral blood with chemotherapy (ie, a <50%
decrease in peripheral blood plasma cells by 10 days of
treatment or persistence of circulating plasma cells after 4
weeks) has been proposed as a marker of unresponsive
disease [1].
Autologous HCT
Given the PFS beneﬁt of high-dose chemotherapy over
conventional-dose chemotherapy in the management of
patients withMM, it was logical to explore the intensiﬁcation
of chemotherapy with high-dose melphalan in patients with
PCL [51,52]. Selected studies on autologous HCT for PCL are
summarized in Table 2. Although small in number, earlier
reports on the use of high-dose chemotherapy (mostly high-
dose melphalan) followed by autologous HCT conﬁrmed the
value of dosage intensiﬁcation in some patients with PCL;
however, the median survival post-HCT ranged from a few
months to almost 5 years [1,2,53-58].Table 2
Selected Studies on Autologous HCT in PCL (Reporting 3 Cases)
Study Number of
Subjects
(Median Age,
Years)
Study Type Preparative Regimen
Drake et al. [50] 272 (55) Registry
(EBMT)
Various (TBI-based, 9.1%)
Mahindra et al. [60] 99 (56) Registry
(CIBMTR)
Various (melphalan-based,
91%; 11% received TBI)
Lebon et al. [72] 17 (N/A) Retrospective Melphalan (single, 16;
tandem, 1)
Pagano et al. [31] 17 (62) Retrospective
(GIMEMA)
Single, 9; tandem, 8
Hovenga et al. [55] 3 (58) Case series MEL200
CIBMTR indicates Center for International Blood andMarrow Transplantation Resea
high-dose melphalan at 200 mg/m2; TBI, total body irradiation; N/A, not availableThe European Group for Blood and Marrow Trans-
plantation has reported the largest retrospective analysis of
patients with pPCL undergoing autologous HCT to date [50].
A total of 272 patients underwent high-dose chemotherapy
conditioning (9.1% with total body irradiationebased
conditioning) between 1980 and 2006. At the time of auto-
grafting, 25.5% of the patients with pPCL were in complete
response (CR), compared with 11.9% in the MM control
group. The pPCL group was more likely to achieve CR at day
100 after autologous HCT (41.2% versus 28.2%), but had an
inferior OS compared with the MM group (25.7 months
versus 62.3 months) [50]. This was likely related to the short
duration of postautografting response and an increased risk
of transplantation-related mortality (TRM), although the
actual rates of TRM were not reported. The median PFS was
lower in the pPCL group despite a younger age and shorter
period from diagnosis to autologous HCT (14.3 months
versus 27.4 months) [50]. The reasons for higher TRM in
patients with pPCL are unclear, although tissue damage from
aggressive disease course and consequent organ function
impairmentmay be suspected. It was also noted that 10.3% in
the pPCL group underwent subsequent allogeneic HCT,
compared with 5.3% in the MM control group.
Achievement of effective cytoreduction is a prerequisite
for durable response after autologous HCT in MM [59];
however, CR as deﬁned by conventional criteria, especially in
PCL, is likely associated with a signiﬁcant minimal residual
disease burden, resulting in eventual relapse post-HCT.
Several reports have conﬁrmed the importance of molec-
ular remission post-HCT for prolonged survival in patients
with PCL [53,57,58]. Some reports including registry data
have examined a tandem autologous HCT approach for PCL
treatment, but they have not been analyzed separately, and
the true value of dose intensiﬁcation on outcomes has not yet
been discerned [31,41,60-62]. Caution is advised in treating
patients with PCL and splenomegaly, given the case report of
splenic rupture after peripheral stem cell mobilization with
cyclophosphamide and granulocyte colony-stimulating
factor in a patient with PCL [63].
The role of maintenance therapy after autologous HCT in
patients with PCL has not been fully evaluated in randomized
controlled trials or prospective studies. Several case reports
have indicated a beneﬁt of IFN-a either after inductionDisease Status at HCT NRM Response Survival
CR, 25.5%; PR, 58.7%;
NR/MR, 8.9%;
REL/PROG, 6.9%
N/A CR, 41.2% at
day þ100
OS, 25.7 months;
PFS, 27.4 months
CR, 20%; PR, 56%;
MR/SD, 14%;
REL/PROG, 1%
3-year
NRM, 5%
3-year relapse
rate, 61%
3-year PFS, 34%,
3-year OS, 64%
N/A N/A CR, 18%; VGPR,
70%; PR,
6%; SD, 6%
(tandem, CR)
N/A
N/A N/A Maintenance, 4 12 relapse, 9 deaths
CR, 100% N/A CR, 100% One death at 3 months
with relapse; 2 alive at
14 and 26 months
rch; EBMT, European Group for Blood andMarrow Transplantation; MEL200,
.
Table 3
Selected Studies on Allogeneic HCT in PCL (Reporting 3 Cases)
Author Number of
Subjects
(Median
Age, Years)
Study Type Preparative Regimen Disease Status
at HCT
GVHD
Prophylaxis
NRM Response Survival
Mahindra
et al. [60]
50 (48) Registry
(CIBMTR)
68% myeloablative; 32%
reduced-intensity
CR, 18%; PR, 46%;
MR/SD, 14%
N/A 41%
(3-year)
38% (3-year) PFS, 20%; OS, 39% (3-year)
Lebovic
et al. [43]
6 (age N/A) Case series Flu/Mel, 3 Relapse after
auto-HCT, 3
N/A N/A N/A Three long-term survivors
at 24, 31, and 42 months
Pagano
et al. [31]
6 (55) Retrospective
(GIMEMA)
Sibling donor, 3; unrelated
donor, 3; tandem auto/
allo-HCT, 4
N/A N/A N/A Maintenance, 1 2 relapse, 3 deaths
Ramasamy
et al. [79]
4 (54) Case series Alemtuzumab/Flu/Mel
(sibling donor, 3; unrelated
donor, 1)
CR, 2; PR, 2 CSA N/A CR, 4 N/A
Johnson
et al. [80]
3 (44) Case series Flu/Mel/ATG, 1; Bu/Cy, 1;
Flu/Cy/ATG, 1 (sibling donor,
2; mismatched related
donor, 1)
NR, 2 N/A N/A N/A Death at 13, 18, and 30
months
ATG indicates antithymocyte globulin; Bu, busulfan; CSA, cyclosporine; Flu/Mel, ﬂudarabine plus melphalan; N/A, not available.
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HCT with some long-term disease control [57,58,64,65].
Thalidomide has been used as maintenance therapy, but has
not been convincingly shown to improve survival in PCL
[35,38]. A single study reported a beneﬁt of bortezomib in
treating relapsed PCL after autologous HCT [66]. Based on
recently published postautologous HCT maintenance data in
patients with MM, the use of lenalidomide maintenance in
patients with PCL may be extrapolated until data are avail-
able for this patient population [67,68].Allogeneic HCT
Allogeneic HCT also has been offered to younger patients
as consolidation therapy, with the potential beneﬁt of a graft-
versus-plasma cell leukemia effect. The true efﬁcacy of this
strategy in PCL remains unknown, however, due primarily to
its low incidence and the paucity of prospective trials of
allogeneic HCT in PCL. Retrospective or registry data appear
to provide the best evidence available thus far. Selected
results of studies of allogeneic HCT in patients with PCL are
summarized in Table 3.
The Center for International Blood and Marrow Trans-
plant Research conducted a retrospective analysis of its
registry data and reported the outcomes of 50 allogeneic HCT
recipients with pPCL between 1995 and 2006 [60]. The
median age was 48 years (compared with 56 years in
autologous HCT recipients), suggesting that this approach
appears to be restricted to younger patients with fewer
comorbidities. At the time of allografting, 18% of the patients
were in CR and 46% were in PR. Only 12% of the patients
received bortezomib before HCT. Thirty-four patients (68%)
received a myeloablative conditioning regimen, and 16 (32%)
received a reduced-intensity conditioning regimen. One-half
of the regimens were melphalan-containing, and 28% were
total body irradiationebased nonemelphalan-containing.
The vast majority of patients (86%) received an allograft
from a related donor. At 3 years, PFS was 20% (95% conﬁdence
interval [CI], 10% to 34%) and OSwas 39% (95% CI, 26% to 54%).
The 3-year cumulative incidence of relapse was 39% (95% CI,
25% to 53%), and 3-year nonrelapse mortality (NRM) was
high, at 41% (95% CI, 29% to 56%). These outcomes (except for
cumulative incidence of relapse) were markedly inferior in
the allograft recipients compared with autograft recipients
[60]. Of note, 26% of the autologous HCTs were tandem
transplantations, and 4% of the autologous HCT recipientsunderwent subsequent allogeneic HCT. Although the study
was limited by its retrospective nature and lack of novel
agentecontaining induction therapy, these results failed to
show an OS beneﬁt for allogeneic HCT.
Although registry data have not demonstrated improved
survival with allogeneic HCT, a retrospective study from our
institution suggested improved outcomes in patients with
PCL with regimens including novel agents [43]. Median OS
was longer in patients receiving bortezomib compared with
thosewho did not (28.4months versus 4months) [43]. Three
long-term survivors had undergone allogeneic HCT, sug-
gesting a beneﬁt associated with this approach. Other single
case reports of allogeneic HCT for PCL have shown similar
results, but these reports might have been subject to publi-
cation bias [69-72].
Interestingly, the use of lenalidomide in the postallogenic
HCT setting was linked to a graft-versus-plasma cell
leukemia effect in a single case report. This interesting
ﬁnding suggests the value of an approach aimed at opti-
mizing adoptive immunotherapy through immunomodula-
tion [73]. This ﬁnding must be evaluated with caution,
however, considering that lenalidomide maintenance
therapy after allogeneic HCT for MM did not appear to be
feasible, owing to an increased risk of graft-versus-host
disease (GVHD) in the Hemato-Oncologie voor Volwasse-
nen Nederland 76 trial [74].DISCUSSION AND RECOMMENDATIONS
Initial rapid control of PCL with systemic therapy appears
to hold the key to successful treatment with consolidation
therapy including HCT in eligible patients [13,60]. One
important prognostic factor that adversely affects OS in both
pPCL and sPCL is a poor response to front-line therapy [31].
Cumulative knowledge, based mainly on retrospective
reviews and case series, demonstrates that combination
chemotherapy regimens containing novel agents, such as
bortezomib and/or lenalidomide, might improve response
rates, PFS, and OS in patients with PCL [13,41,75]. Although
participation in clinical trials is always strongly recom-
mended, this might not be feasible, due in part due to the
paucity of speciﬁc studies on PCL. In the absence of a suitable
clinical trial, it is reasonable to initiate bortezomib-
containing multiagent combination chemotherapy in
patients with newly diagnosed PCL, with the aim of
achieving a VGPR or better. Examples of such combinations
Table 4
Currently Available Clinical Trials Using Chemotherapy for PCL (ClinicalTrials.gov)*
Study Title Study ID
Bortezomib in combination with liposomal doxorubicin and dexamethasone to treat PCL NCT01328236
A study of ARRY-520 (selective kinesin spindle protein inhibitor) in patients with relapsed or refractory MM (includes PCL) NCT00821249
A study of ARRY-520 and bortezomib plus dexamethasone in patients with relapsed/refractory MM (includes PCL) NCT01248923
ARRY-520 plus carﬁlzomib for MM (includes PCL) NCT01372540
Carﬁlzomib and stem cell transplant for plasma cell myeloma (includes PCL) NCT01658904
Oncaspar (PEG-asparaginase)/liposomal doxorubicin/dexamethasone in patients with refractory lymphoid malignancies (includes PCL) NCT00837200
* Accessed on November 25, 2012.
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asone, and bortezomib in combination with multiagent
chemotherapy such as dexamethasone, thalidomide,
continuous-infusion cisplatin, doxorubicin, cyclo-
phosphosphamide, and etoposide. Prevention of tumor lysis
syndrome is mandatory in patients with a high tumor
burden. Lenalidomide-based induction might not be suitable
in a subset of patients with suboptimal renal function.
Although there are no ofﬁcial response criteria for PCL
treatment, van de Donk et al. [13] proposed criteria to facil-
itate the uniform reporting of trial outcomes in patients with
PCL, and the International MyelomaWorking Group recently
proposed a set of response criteria for PCL [76].
Two large registry datasets comprising patients under-
going autologous HCT for pPCL reported similar 3-year
PFS (34% and 38%) but different 3-year OS (39% and 64%)
[50,60]. Those studies show promising survival rates, with
reasonable toxicities, with the use of autologous HCT as
a consolidation strategy after initial response to induction
chemotherapy. The proportion of patients who could not
undergo autologous HCT because of early mortality from
disease progression or TRM is not known, however [13]. It is
highly possible that the success rate of autologous HCT may
be overestimated because of selection bias. Moreover, these
registry studies have some limitations, including data
collected over a long period that do not reﬂect contemporary
practice patterns.
Although autologous HCT may offer superior consolida-
tion of responses compared with chemotherapy alone, the
duration of response is generally short, and only a small
proportion of patients ultimately achieve long-term disease
control. Allogeneic HCT has been examined as a consolida-
tion method for improving unacceptable outcomes in
patients with PCL, but the results indicate disappointingly
high TRM based on registry data [60]. The risk of relapse was
lower in recipients of allogeneic HCT compared with recipi-
ents of autologous HCT, but OSwasworse, owing primarily to
high TRM [60]. Interestingly, a higher proportion of patients
with PCL underwent allogeneic HCT compared with patients
with MM, likely reﬂecting a practice bias favoring the use of
allogeneic HCT in these younger patients, owing to the
disease’s aggressive clinical behavior and projected poor
prognosis [13]. Some authors have also argued that the risk
of TRM in allogeneic HCT is now diminished with the use of
reduced-intensity conditioning regimens (eg, ﬂudarabine
plus melphalan) and perhaps improved supportive care and
incorporation of novel agents [43].
We recommend that eligible patients with PCL demon-
strating a response to induction therapy be promptly referred
to a transplant center to be evaluated for eligibility for HCT as
a consolidative strategy. For younger, ﬁt patients with
adequate organ function and a suitable HLA-matched donor,
allogeneic HCT is the preferred approach. Available allogeneic
HCT options include reduced-intensity conditioningregimens and a tandem autologous-allogeneic HCT strategy
that combines the beneﬁts of cytoreductive therapy and
adoptive immunotherapy. The use of myeloablative regimens
for PCL may be justiﬁed only in younger patients without
associated comorbidities within the context of prospective
clinical trials whenever possible. Conversely, for patients in
whom an unacceptably high mortality from allografting is
anticipated, autologous HCT remains the preferred con-
solidative approach. Moreover, it is reasonable to consider
posttransplantation maintenance strategies incorporating
novel agents for PCL, although data to support such
approaches are limited. These posttransplantation therapies
could further improve thequalityof responses andpotentially
translate into improved survival.
A maintenance approach should be considered for older
and/or more frail patients who attain remission after
induction therapy (with, eg, a bortezomib-based regimen or
other regimens) but are not appropriate candidates for
autologous or allogeneic HCT. The roles of novel proteasome
inhibitors, such as carﬁlzomib, and immunomodulatory
agents, such as pomalidomide, remain unclear, but these
agents may be beneﬁcial in this setting. Accordingly, the
integration of these agents into combination regimens as
part of the treatment paradigm of PCL remains an interesting
research question. In addition, the development of therapies
that circumvent drug resistance is of paramount importance
for the management of both PCL and MM.
FUTURE DIRECTIONS
There is a signiﬁcant need for studies exploring the role of
novel therapeutic approaches for PCL. Novel proteasome
inhibitors, immunomodulatory agents, histone deacetylase
inhibitors, and monoclonal antibodies are attractive agents
to examine in PCL therapy. Development of complex treat-
ment algorithms that combine novel agents as induction
therapy, as part of conditioning regimens for autologous or
allogeneic HCT, or as posttransplantation remission strate-
gies are logical and might translate into improved outcomes
in patients with PCL. In addition, the use of novel genomic
data and biomarkers for PCL may help guide treatment
decisions toward particular therapeutic modalities while
minimizing unnecessary toxicities. Currently registered open
clinical trials for PCL are listed in Table 4. CD20 might be
expressed at higher frequency in PCL compared with MM,
suggesting a possible role for anti-CD20 monoclonal anti-
body therapy for this disease [2,62,77].
With regard to further optimization of autologous HCT
strategies, the addition of novel agents, evaluation of new
conditioning regimens, role of tandem autologous HCT,
consolidation chemotherapy after autologous HCT, and
maintenance therapy all merit further investigation within
the context of well-designed clinical trials. Finally, concerted
and collaborative efforts are essential to the development of
comprehensive approaches under prospective trials to
T. Nishihori et al. / Biol Blood Marrow Transplant 19 (2013) 1144e11511150evaluate the role of reduced-intensity conditioning alloge-
neic HCT in patients with PCL as consolidation therapy with
a curative intent to maximize the putative graft-versus-
plasma cell leukemia effect and improve treatment
outcomes for patients with this dreadful disease.ACKNOWLEDGMENTS
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